Abstract:
본 발명은 신규 피페라지닐프로필피라졸 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물에 관한 것이다. 본 발명의 신규 피페라지닐프로필피라졸 유도체는 도파민 D 4 수용체 친화력이 우수하고, 아포몰핀(Apomorphine)으로 유도된 마우스의 정신병적 행동 (Cage climbing, 철망 기어오르기)을 효과적으로 억제하였을 뿐만 아니라 마우스 로타로드 (rotarod) 시험에서 비교적 약한 부작용을 나타내므로, 중추신경계 질환 구체적으로는 정신분열증, 주의력결핍 과잉행동장애, 우울증, 스트레스성 질환, 공황장애, 공포증, 강박장애, 외상후 스트레스장애, 인식장애, 알츠하이머병, 파킨슨병, 불안증, 망상분열증, 열광증, 경련장애, 인격장애, 편두통, 약물중독, 알코올 중독, 비만, 섭식 장애, 수면장애 등의 치료 및 예방제로 유용하다. 피라졸, 피페라진, 도파민 D4 수용체, 중추신경계 질환, 정신분열증
Abstract:
A piperazinyl-propyl-pyrazole derivative is provided to show excellent dopamine D4 affinity, inhibit the psychotic action of a mouse induced by apomorphine and exhibit relatively weak side effect at a mouse rotarod test, thereby being effectively used as a therapeutic and prophylactic agent of central nervous system diseases. A piperazinyl-propyl-pyrazole derivative is represented by a formula(1). In the formula(1), R^1 is C1-10 alkyl, or substituted or unsubstituted aryl or heteroaryl; one of R^2 or R^3 is H, and the other one of R^2 or and R^3 is C1-10 alkyl, benzyl, or substituted or unsubstituted aryl or heteroaryl; each R^4, R^5, R^6, and R^7 is independently H or C1-10 alkyl; each R^8, R^9, R^10, R^11 and R^12 is independently H, halogen, C1-10 alkyl, C1-C10 alkoxy, bis(substituted or unsubstituted aryl)alkylene, benzyl, nitro, hydroxy, cyano, amino, mono- or di-alkylamino, alkylcarbonylamino, aminosulfonyl, mono- or di-alkylaminosulfonyl, alkylcarbonyl, or alkyloxycarbonyl; and a dotted line is a single-bonded line or a double bond, wherein the aromaticity of a pyrazole-ring should be maintained, the aryl is phenyl, the heteroaryl is thiophenyl or pyridyl, and the substituted aryl or heteroaryl is an aryl or a heteroaryl substituted with one to three substituent(s) selected from the group consisting of halogen, nitro, C1-10 alkyl, C1-10 alkoxy, C1-10 haloalkyl, and C1-10 haloalkoxy. A method for preparing the piperazinyl-propyl-pyrazole derivative comprises a step of subjecting a pyrazole aldehyde derivative represented by a formula(2) and a piperazine derivative represented by a formula(3) to a reductive amination reaction. A pharmaceutical composition for treating central nervous system diseases comprise the compound of the formula(1).